Dan Burgess joined the CARB-X Joint Oversight Board as Independent Chair in January 2023. He currently serves as Chair and CEO of Pulmocide Ltd., a company that is advancing a novel inhaled anti-fungal through a Phase 3 clinical trial registration program. Burgess was previously founder, President and CEO of Rempex Pharmaceuticals, Inc., an antibiotic company that was sold to the Medicines Company (now Novartis). Two antibiotics developed by Rempex have since been approved by the FDA. Prior to Rempex, he was President and CEO of Mpex Pharmaceuticals, Inc., a company that advanced an inhaled antibiotic for cystic fibrosis patients into Phase 3 clinical trials before it was acquired by Aptalis (now Abbvie). The product was approved in Europe and Canada. Burgess is also a Venture Partner with SV Health Investors, a venture capital firm, and he serves as a director of several public and private biotechnology companies. He is also a Director and Emeritus Chair of Biocom California, a trade organization representing the California biotechnology industry with more than 1700 member companies.

Burgess received an A.B. in economics from Stanford University, and an M.B.A. from Harvard Business School.